Nephrolytix
Berlin, Germany
The standard of care for AKI detection in clinical routine is based on a biomarker measurement and takes 48 to 72 hours to yield results, thus leading to delayed therapeutic intervention. Translating the scientific expertise in kidney function measurement into clinical routine, Nephrolytix utilizes a database, a protocol for contrast agent measurement, and a proprietary software to diagnose AKI within the first two to seven hours – less than one tenth of the standard timeline. Nephrolytix is easy to integrate into today’s clinical workflow everywhere and, given low component costs, promises a step-changing improvement in both patient outcomes and healthcare system performance.
Only accessible to MedStartr community members.
Join nowCompany Info
- Founded
- 2022
- Website
- www.nephrolyx.com/
Only accessible to MedStartr community members.
Join nowWhat do you think of Nephrolytix?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.
Only accessible to MedStartr community members.
Join now